Xeris Biopharma Holdings Inc [NASDAQ: XERS] price surged by 15.03 percent to reach at $0.29.
The one-year XERS stock forecast points to a potential upside of 51.53. The average equity rating for XERS stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Xeris Biopharma Holdings Inc [XERS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XERS shares is $4.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XERS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Xeris Biopharma Holdings Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 28, 2024. While these analysts kept the previous recommendation, Craig Hallum raised their target price to Buy. The new note on the price target was released on August 28, 2023, representing the official price target for Xeris Biopharma Holdings Inc stock. Previously, the target price had yet another raise to $4, while Jefferies analysts kept a Buy rating on XERS stock.
The Average True Range (ATR) for Xeris Biopharma Holdings Inc is set at 0.13, with the Price to Sales ratio for XERS stock in the period of the last 12 months amounting to 1.92.
XERS Stock Performance Analysis:
Xeris Biopharma Holdings Inc [XERS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.45. With this latest performance, XERS shares gained by 26.86% in over the last four-week period, additionally plugging by 24.02% over the last 6 months – not to mention a drop of -13.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XERS stock in for the last two-week period is set at 67.51, with the RSI for the last a single of trading hit 74.55, and the three-weeks RSI is set at 61.20 for Xeris Biopharma Holdings Inc [XERS]. The present Moving Average for the last 50 days of trading for this stock 1.9400, while it was recorded at 1.9900 for the last single week of trading, and 2.1300 for the last 200 days.
Insight into Xeris Biopharma Holdings Inc Fundamentals:
Xeris Biopharma Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.81 and a Current Ratio set at 2.37.
Xeris Biopharma Holdings Inc [XERS] Institutonal Ownership Details
The top three institutional holders of XERS stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in XERS stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in XERS stock with ownership which is approximately 5.8386%.
